EGFR Inhibitors-related Panniculitis: A New Side Effect

Epidermal growth factor receptor (EGFR) inhibitors are widely used in the treatment of advanced malignancies, and their skin toxicity is frequent and well recognized in the literature. We report the case of a 69-year-old patient with a history of adenocarcinoma of the lung treated with several EGFR...

Descripción completa

Detalles Bibliográficos
Autores principales: Lopes, Sofia, Nogueira, Ana, Pardal, Joana, Azevedo, Filomena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6536062/
https://www.ncbi.nlm.nih.gov/pubmed/31149582
http://dx.doi.org/10.4103/idoj.IDOJ_273_18
_version_ 1783421691945287680
author Lopes, Sofia
Nogueira, Ana
Pardal, Joana
Azevedo, Filomena
author_facet Lopes, Sofia
Nogueira, Ana
Pardal, Joana
Azevedo, Filomena
author_sort Lopes, Sofia
collection PubMed
description Epidermal growth factor receptor (EGFR) inhibitors are widely used in the treatment of advanced malignancies, and their skin toxicity is frequent and well recognized in the literature. We report the case of a 69-year-old patient with a history of adenocarcinoma of the lung treated with several EGFR inhibitors and the development of skin lesions compatible with panniculitis. The reproducibility of the lesions with different inhibitors reinforces the causal relationship with the drug, representing the first report in the literature of this side effect.
format Online
Article
Text
id pubmed-6536062
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-65360622019-05-30 EGFR Inhibitors-related Panniculitis: A New Side Effect Lopes, Sofia Nogueira, Ana Pardal, Joana Azevedo, Filomena Indian Dermatol Online J Case Report Epidermal growth factor receptor (EGFR) inhibitors are widely used in the treatment of advanced malignancies, and their skin toxicity is frequent and well recognized in the literature. We report the case of a 69-year-old patient with a history of adenocarcinoma of the lung treated with several EGFR inhibitors and the development of skin lesions compatible with panniculitis. The reproducibility of the lesions with different inhibitors reinforces the causal relationship with the drug, representing the first report in the literature of this side effect. Wolters Kluwer - Medknow 2019 /pmc/articles/PMC6536062/ /pubmed/31149582 http://dx.doi.org/10.4103/idoj.IDOJ_273_18 Text en Copyright: © 2019 Indian Dermatology Online Journal http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Case Report
Lopes, Sofia
Nogueira, Ana
Pardal, Joana
Azevedo, Filomena
EGFR Inhibitors-related Panniculitis: A New Side Effect
title EGFR Inhibitors-related Panniculitis: A New Side Effect
title_full EGFR Inhibitors-related Panniculitis: A New Side Effect
title_fullStr EGFR Inhibitors-related Panniculitis: A New Side Effect
title_full_unstemmed EGFR Inhibitors-related Panniculitis: A New Side Effect
title_short EGFR Inhibitors-related Panniculitis: A New Side Effect
title_sort egfr inhibitors-related panniculitis: a new side effect
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6536062/
https://www.ncbi.nlm.nih.gov/pubmed/31149582
http://dx.doi.org/10.4103/idoj.IDOJ_273_18
work_keys_str_mv AT lopessofia egfrinhibitorsrelatedpanniculitisanewsideeffect
AT nogueiraana egfrinhibitorsrelatedpanniculitisanewsideeffect
AT pardaljoana egfrinhibitorsrelatedpanniculitisanewsideeffect
AT azevedofilomena egfrinhibitorsrelatedpanniculitisanewsideeffect

Ejemplares similares